ES2992761T3 - Humanized anti-cd3 antibodies, conjugates and uses thereof - Google Patents

Humanized anti-cd3 antibodies, conjugates and uses thereof Download PDF

Info

Publication number
ES2992761T3
ES2992761T3 ES17748229T ES17748229T ES2992761T3 ES 2992761 T3 ES2992761 T3 ES 2992761T3 ES 17748229 T ES17748229 T ES 17748229T ES 17748229 T ES17748229 T ES 17748229T ES 2992761 T3 ES2992761 T3 ES 2992761T3
Authority
ES
Spain
Prior art keywords
amino acid
antibody
acid sequence
sequence comprises
comprises seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17748229T
Other languages
English (en)
Spanish (es)
Inventor
Chanhyuk Kim
Travis Young
Minsoo Kim
Jennifer Ma
Leonard Presta
Peter G Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2992761T3 publication Critical patent/ES2992761T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17748229T 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof Active ES2992761T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291143P 2016-02-04 2016-02-04
PCT/US2017/016407 WO2017136659A2 (en) 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof

Publications (1)

Publication Number Publication Date
ES2992761T3 true ES2992761T3 (en) 2024-12-17

Family

ID=59501004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17748229T Active ES2992761T3 (en) 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof

Country Status (9)

Country Link
US (1) US12252534B2 (enExample)
EP (1) EP3411069B1 (enExample)
JP (2) JP6951826B2 (enExample)
KR (1) KR102891788B1 (enExample)
CN (1) CN109069635B (enExample)
AU (1) AU2017213886B2 (enExample)
CA (1) CA3013463C (enExample)
ES (1) ES2992761T3 (enExample)
WO (1) WO2017136659A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
ES2992761T3 (en) 2016-02-04 2024-12-17 Scripps Research Inst Humanized anti-cd3 antibodies, conjugates and uses thereof
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
BR112021003843A2 (pt) * 2018-08-28 2021-05-25 Ambrx, Inc. biconjugados de folato de anticorpo anti-cd3 e seus usos
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
WO2020168555A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
AU2020359928B2 (en) * 2019-09-30 2025-01-09 Harbour Biomed (Shanghai) Co., Ltd. CD3-targeting antibody, bispecific antibody and use thereof
US20220411530A1 (en) * 2019-11-22 2022-12-29 Nantong Yichen Biopharma. Co. Ltd. PSMA Antibody and Use Thereof
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
IL300256A (en) 2020-08-25 2023-03-01 Gilead Sciences Inc Multispecific Antigen Binding Molecules Targeting HIV and Methods of Use
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
KR20240043784A (ko) * 2021-08-09 2024-04-03 메르크 파텐트 게엠베하 염증유발성 시토카인의 방출로부터 t 세포-매개 종양 세포독성을 디커플링시키는 단백질
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
JP2025540657A (ja) * 2022-11-18 2025-12-16 ジェイエヌ バイオサイエンシーズ エルエルシー 抗ｃｄ３抗体
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
EP4682170A1 (en) * 2023-03-13 2026-01-21 Mustbio Co., Ltd. Novel cd3-binding antibody and multispecific antibody comprising same

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
CA2507749C (en) 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US7326685B2 (en) 2001-09-21 2008-02-05 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
WO2005098998A1 (ja) 2004-03-30 2005-10-20 Kureha Corporation 非水電解質二次電池用負極材料、その製造方法、負極および電池
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
KR20080079643A (ko) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 비-천연 아미노산을 포함하는 방법 및 조성물
AU2006326404B2 (en) 2005-12-14 2011-11-03 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1978989A4 (en) 2005-12-30 2009-03-18 Ambrx Inc AMINO ACIDS AND NON-NATURAL POLYPEPTIDES, COMPOSITIONS CONTAINING THEM, METHODS INVOLVING THEM AND USES THEREOF
EP1974025A4 (en) 2006-01-19 2009-03-11 Ambrx Inc NON-NATURAL AMINO ACID POLYPEPTIDES WITH MODULATED IMMUNOGENICITY
KR20090100407A (ko) 2006-12-18 2009-09-23 암브룩스, 인코포레이티드 비천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비천연 아미노산 및 폴리펩티드의 용도
JP2010514808A (ja) 2006-12-28 2010-05-06 アンブルックス，インコーポレイテッド フェナジンまたはキノキサリンで置換されたアミノ酸およびポリペプチド
EP3838298B1 (en) 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
CA2723816C (en) 2008-05-13 2017-06-20 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
PT2337846T (pt) 2008-09-26 2018-04-05 Ambrx Inc Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais
US20120189621A1 (en) 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
ES2732213T3 (es) * 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
EP2714684B1 (en) 2011-05-27 2018-09-05 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
BR112013030362B1 (pt) 2011-05-27 2022-08-30 Ambrx, Inc Composto derivado de dolastatina, método para derivatizar o mesmo e composição farmacêutica que compreende o dito composto
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SG10201705787VA (en) 2012-09-27 2017-08-30 Merus Nv BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
EP2904016B1 (en) 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
HK1211299A1 (en) 2013-02-26 2016-05-20 罗切格利卡特公司 Bispecific t cell activating antigen binding molecules
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
WO2014185985A1 (en) 2013-05-14 2014-11-20 Ambrx, Inc. Novel polypeptide small molecule conjugates and their uses
MX366449B (es) 2013-06-07 2019-07-09 Rhizen Pharmaceuticals Sa Inhibidores de pi3 cinasa delta y gama selectivos duales.
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
KR20160090308A (ko) 2013-11-04 2016-07-29 그렌마크 파머수티칼스 에스. 아. T 세포 재표적 이형-이량체 면역글로불린의 생산
EP3192812B1 (en) 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
ES2992761T3 (en) 2016-02-04 2024-12-17 Scripps Research Inst Humanized anti-cd3 antibodies, conjugates and uses thereof

Also Published As

Publication number Publication date
JP6951826B2 (ja) 2021-10-20
AU2017213886A1 (en) 2018-08-16
CA3013463A1 (en) 2017-08-10
CA3013463C (en) 2024-05-21
AU2017213886B2 (en) 2024-03-07
US20230192844A1 (en) 2023-06-22
KR20180104157A (ko) 2018-09-19
CN109069635B (zh) 2023-09-26
JP2022023052A (ja) 2022-02-07
EP3411069A2 (en) 2018-12-12
JP2019512002A (ja) 2019-05-09
KR102891788B1 (ko) 2025-11-26
CN109069635A (zh) 2018-12-21
EP3411069A4 (en) 2020-02-19
EP3411069B1 (en) 2024-07-10
WO2017136659A3 (en) 2017-09-08
US12252534B2 (en) 2025-03-18
WO2017136659A2 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
ES2992761T3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
CN105283201B (zh) 靶向剂抗体偶联物及其用途
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
ES2866398T3 (es) Construcciones de anticuerpos multiespecíficos
ES2689470T3 (es) Anticuerpos de Fab-Fv de conector único y métodos para producirlos
AU2019272250A1 (en) Anti-mesothelin antibody and antibody-drug conjugate thereof
BR112021003843A2 (pt) biconjugados de folato de anticorpo anti-cd3 e seus usos
EP3710485A1 (en) Anti-sez6 antibody drug conjugates and methods of use
TW201813671A (zh) 抗ｃ－Ｍｅｔ抗體－細胞毒性藥物偶聯物的醫藥用途
JP2020532543A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
HK40000405A (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK40000405B (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
KR20250084865A (ko) PSMA-STEAP1 이중 가변 도메인 면역글로불린 (DVD-Ig) 분자 및 약물 접합체
HK40016895A (en) Targeting agent antibody conjugates and uses thereof
HK1219887B (zh) 靶向剂抗体偶联物及其用途